SynAct Pharma AB
STO:SYNACT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Adroit Infotech Ltd
NSE:ADROITINFO
|
IN |
SynAct Pharma AB
Total Liabilities
SynAct Pharma AB
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
SynAct Pharma AB
STO:SYNACT
|
Total Liabilities
kr50.2m
|
CAGR 3-Years
46%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Total Liabilities
kr283.6m
|
CAGR 3-Years
5%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Total Liabilities
kr168.9m
|
CAGR 3-Years
18%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Total Liabilities
kr3.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
62%
|
CAGR 10-Years
31%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Total Liabilities
kr29.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
23%
|
|
|
BioArctic AB
STO:BIOA B
|
Total Liabilities
kr608.1m
|
CAGR 3-Years
104%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
SynAct Pharma AB
Glance View
SynAct Pharma AB engages in the development of pharmaceutical drugs for the treatment of inflammatory diseases. The company is headquartered in Lund, Skane. The company went IPO on 2016-07-11. The firm is located in Lund, Sweden. The company develops medicines for acute impairment in inflammatory diseases. The firm's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.
See Also
What is SynAct Pharma AB's Total Liabilities?
Total Liabilities
50.2m
SEK
Based on the financial report for Dec 31, 2025, SynAct Pharma AB's Total Liabilities amounts to 50.2m SEK.
What is SynAct Pharma AB's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
54%
Over the last year, the Total Liabilities growth was -11%. The average annual Total Liabilities growth rates for SynAct Pharma AB have been 46% over the past three years , 54% over the past five years .
